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PRECLINICAL STUDY
dventitial Microvessel Formation
fter Coronary Stenting and the Effects
f SU11218, a Tyrosine Kinase Inhibitor
sim N. Cheema, MD, PHD, FACC,* Tony Hong,* Nafiseh Nili, PHD,* Amit Segev, MD,*
ohn G. Moffat, PHD,† Kenneth E. Lipson, PHD,† Anthony R. Howlett, PHD,†
avid W. Holdsworth, PHD,‡ Michael J. Cole, MESC,‡ Beiping Qiang, MD,* Frank Kolodgie, PHD,§
enu Virmani, MD, FACC,§ Duncan J. Stewart, MD, FACC,* Bradley H. Strauss, MD, PHD, FACC*
oronto and London, Ontario, Canada; South San Francisco, California; and Washington, DC
OBJECTIVES The aim of this study was to delineate the temporal profile of adventitial microvessel
(Ad-MV) formation after stenting, its relationship to arterial wall hypoxia, and the effects
of a tyrosine kinase inhibitor (TKI), SU11218, on Ad-MV and in-stent intimal
hyperplasia (IH).
BACKGROUND Adventitial microvessels have been reported after arterial injury; however, the underlying
stimulus for this response and its relationship to IH is unknown.
METHODS Coronary stenting was performed in 40 pigs randomized to SU11218 (n  20) or placebo
(n  20). Vessel wall hypoxia was assessed by pimonidazole adducts and hypoxia-inducible
factor (HIF)-1 alpha expression. Adventitial microvessels were quantified by three-
dimensional microscopic computed tomography (3D micro CT). Intimal hyperplasia was
measured by intravascular ultrasound (IVUS), 3D micro CT, and morphometry. The effects
of SU11218 were assessed in vitro on smooth muscle cell (SMC) and endothelial cell (EC)
functions and in vivo on Ad-MV and IH.
RESULTS Hypoxia was evident in the vessel wall at 48 h and persisted for four weeks. Adventitial
microvessels increased significantly at one week (24  7 microvessels/segment) and four
weeks (23 7 microvessels/segment) compared with uninjured arteries (16 2 microvessels/
segment; p  0.001) and correlated with IH (r  0.77, p  0.001). The TKI SU11218
inhibited platelet-derived growth factor receptor–beta phosphorylation, EC and SMC DNA
synthesis, and migration in a dose-dependent manner in vitro and significantly inhibited
Ad-MV (16  5 vs. 23  7 microvessels/segment in placebo, p  0.001) and produced
approximately 80% reduction in IH (0.52  0.51 mm2 vs. 2.47  1.66 mm2 in placebo, p 
0.001) at four weeks in vivo.
CONCLUSIONS Arterial stenting causes arterial wall hypoxia followed by Ad-MV formation. The TKI
SU11218 inhibits both Ad-MV formation and IH and represents a promising therapeutic
agent to prevent in-stent restenosis. (J Am Coll Cardiol 2006;47:1067–75) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.076American College of Cardiology Foundation
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she precise role of the adventitial layer in modulating the
eointimal response after coronary stenting remains unclear.
revious studies have indicated that adventitial myofibroblasts
ight migrate toward the arterial lumen and contribute to
ntimal hyperplasia (1). Other studies have described changes
n the extracellular matrix within the adventitia (2,3). Recently,
here has been growing interest in the potential role of the
dventitial vasa vasorum in the arterial repair process after
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ccepted August 15, 2005.njury. Although an increase in adventitial microvessels (Ad-
V) has been reported after experimental balloon injury (4,5),
he underlying stimuli leading to the Ad-MV response have
ot been elucidated and it is unknown whether a similar
esponse is present after arterial stenting.
Tissue hypoxia is a potent stimulus for expression of vascular
ndothelial growth factor (VEGF) and platelet-derived growth
actor (PDGF) (6,7), two growth factors that play critical roles
n the formation of new blood vessels. The VEGF initiates
ngiogenesis by stimulating endothelial cell (EC) proliferation
nd the formation of endothelial tubes, whereas PDGF and its
eceptor, platelet-derived growth factor receptor-beta
PDGFR-), play a central role in the recruitment of pericytes
nd smooth muscle cell (SMC) to form stable and mature
icrovessels (8,9). Both VEGF and PDGF receptors mediate
ell signaling through receptor tyrosine kinases that might
erve as an important target for the development of novel
nti-angiogenic therapies (10,11).
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Adventitial Microvessels After Stenting March 7, 2006:1067–75In this study we assessed serial changes in Ad-MV in a
orcine coronary stenting model and the presence of tissue
ypoxia as a stimulus of such changes. Furthermore, we
dministrated SU11218, a class III tyrosine kinase inhibitor
TKI), to study the effects of VEGF and PDGF receptor
nhibition on Ad-MV formation and intimal hyperplasia (IH).
ETHODS
nimal model. Experiments were performed in accor-
ance with guidelines set out by the University of Toronto
nd approved by the St. Michael’s Hospital Animal Care
ommittee. Coronary stenting was performed in 40 cas-
rated male Yorkshire pigs weighing 25 to 30 kg as
ummarized in Figure 1. Animals received intravenous
eparin (200 U/kg), and stents (EXPRESS, Boston Scien-
ific, Inc., Natick, Massachusetts) were deployed in the
ircumflex artery, with a 1:1 stent-to-artery ratio. Intravas-
ular ultrasound (IVUS) was performed with a 40-MHz
ltraCross (Boston Scientific, Inc.) catheter before and
fter the procedure. All animals received aspirin 325 mg
aily. Repeat angiography was performed at end study (48
, 1 week, or 4 weeks). Intravascular ultrasound follow-up
as only done at four weeks. Animals were treated with
ither subcutaneous injections of placebo or the TKI
U11218 (5 mg/kg, SUGEN, Inc., San Francisco, Califor-
ia), twice a week for 4 weeks, starting 1 day before
tenting. This dosing schedule achieved a mean plasma
oncentration of 3.2 nmol/l (range 2.5 to 5.0 nmol/l, n  4
Abbreviations and Acronyms
3D micro CT  three-dimensional microscopic
computed tomography
Ad-MV  adventitial microvessels
BrdU  bromo-dexoyuridine
CA-EC  coronary artery endothelial cells
CA-SMC  coronary artery smooth muscle cells
CSA  cross-sectional area
EC  endothelial cells
HIF  hypoxia-inducible factor
IH  in-stent intimal hyperplasia
IVUS  intravascular ultrasound
PDGF  platelet-derived growth factor
SMC  smooth muscle cells
TKI  tyrosine kinase inhibitor
VEGF  vascular endothelial growth factorFigure 1. Study protocol: the number of vesigs) without any adverse effects on histopathology of
nternal organs (liver, kidney, pancreas, adrenals, skeletal
uscle, salivary gland, bone marrow, and myocardial tissue).
he molecular weight of SU11218 is 457 Da.
ntravascular ultrasound. Intravascular ultrasound images
ere analyzed with a digital video analyzer during manual
ullback and at regular intervals by an observer blinded to
he treatment allocation. Intimal cross-sectional area (CSA)
as measured at three sites (proximal, middle, and distal)
ithin the stented segments, and a mean intimal CSA was
etermined.
hree-dimensional microscopic computed tomography. The
rteries were processed and scanned with minor modifica-
ions of previously published protocol (4). After sacrifice,
earts were perfused with 500 ml of heparinized saline,
ollowed by 60 to 80 ml of a low-viscosity radio opaque
olymer, MV 122 (Flowtech, Inc., Carver, Massachusetts)
t 90 mm Hg until it was flowing freely through the
oronary sinus. Hearts were placed in 10% buffered formalin
t 4° C for 24 h to allow polymerization of the compound.
he stented segments were removed and placed in glycerol
30%, 50%, 70%, and 100% for 24 h each) before paraffin
mbedding. The specimens were scanned with three-
imensional microscopic computed tomography (3D micro
T) (eXplore MS Micro CT, GE Healthcare, London,
anada) at 90 kVp (75 A) with a filter composed of
opper (0.25 mm) and aluminum (0.25 mm) to reduce CT
rtifacts from stent struts. Images were acquired at 0.5°-
teps over 360° and reconstructed into three-dimensional
olumes of 16-m resolution using true Feldkamp cone
eam filtered back projection algorithm (12).
d-MV. The 3D micro CT scan of each stented segment
as divided into 10 cross-sections, and the number of
icrovessels in the arterial adventitia (defined as a 1.0-mm
nnular perimeter around the stent struts) were counted in
ach cross-section and a segment mean determined
Fig. 2A). Maximum intensity projections were obtained
hrough 3D volume images to assess the spatial distribution
f the microvessels (Fig. 2B). In addition, CSA of Ad-MVs
as measured with computerized image analysis software
Image J, Bethesda, Maryland) in five cross-sections of each
tented artery and a mean Ad-MV CSA was determined in
4-week group of placebo- and SU11218-treated animals.
orphometric measurements. After scanning, stented
egments were embedded in plastic and cut into 4-m-thicksels analyzed and time points studied.
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March 7, 2006:1067–75 Adventitial Microvessels After Stentingections. Movat pentachrome stained sections obtained
rom three sites (proximal, mid, and distal) within the
tented segment were used to assess injury scores according
o Schwartz et al. (13). Lumen and intimal CSA were
easured with image analysis software (Scion, Frederick,
aryland).
issue hypoxia. Animals were injected with 200 mg of
imonidazole (Hypoxyprobe, Chemicon International, Inc.,
emecula, California) intravenously 60 min before tissue
arvesting. Pimonidazole forms irreversible adducts with
ntracellular macromolecules under hypoxic conditions (14).
his technique identifies tissue pO2 levels of 10 mm Hg
15). For western immunoblotting, tissue extracts contain-
igure 2. Cross-sectional (A) and maximum intensity projection (B)
mages of a three-dimensional microscopic computed tomography (3D
icro CT) scan of stented artery for assessment of adventitial microvessels
Ad-MV). (A), radio-opaque contrast can be seen in the main artery as well
n the Ad-MV (arrow). Contrast-filled microvessels were counted in the
edia/adventitia, defined as a 1.0-mm annular area surrounding the stent
truts. 1 lumen cross-sectional area (CSA); 2 intima CSA; 3 arterial
edia/adventitia. (B), 3D micro CT shows detail of Ad-MV around stent
truts. White bars  2 mm.ng 50 g of proteins were separated by 4% to 20% sodium Todecyl sulphate polyacrylamide gels (SDS-PAGE) and
lectrotransferred onto a nitrocellulose membrane. Mem-
ranes were immunoblotted with anti-pimonidazole mono-
lonal antibody (Chemicon International, Inc.) for detec-
ion of pimonidazole adducts. Western immunblotting was
lso performed under the same conditions with anti–hypoxia-
nducible factor (HIF)-1alpha monoclonal IgG 2b (Clone
1alpha67, Novous Biologicals, Littleton, Colorado) for
IF-1 alpha expression. Detection was performed with a
hemiluminescence peroxidase detection system (Sigma, St.
ouis, Missouri) and exposure to BioMax film (Kodak,
ochester, New York). Ischemic skeletal muscle from por-
ine lower hind limb, obtained 6 h after occlusion of
xternal iliac artery, served as a positive control. Protein
oading was assessed by Ponceau-red staining. Densitomet-
ic analysis of the immuno bands for HIF-1 alpha, pi-
onidazole adducts, and the ponceau red bands was per-
ormed with ImageQuant TL software (Amersham
iosciences Corp., Piscataway, New Jersey) to correct for
rotein loading. Immunohistochemistry was done on arte-
ial cross-sections with the anti-piminidazole antibody (1:
00 dilution).
U11218 in vitro studies. Human CA-SMC and CA-EC
ere obtained from Clonetics (Cambrex, Inc., East Ruth-
rford, New Jersey) and maintained in SmGM-2 and
GM-2MV medium, respectively.
NA synthesis. The effects of SU11218 on CA-SMC
nd CA-EC DNA synthesis were assessed by bromo-
exoyuridine (BrdU) incorporation. Quiescent cells were
xposed to increasing concentrations of SU11218 and stim-
lated with either PDGF (100 ng/ml, Roche Molecular,
ndianapolis, Indiana) or VEGF (20 ng/ml, R & D Sys-
ems, Minneapolis, Minnesota) for CA-SMC and CA-EC,
espectively. After 16 h, BrdU was added to the cultures for
wo additional hours of incubation. The cells were then
xed and BrdU incorporation was assessed by ELISA
Roche Diagnostics).
igration assay. Cells were made quiescent by overnight
ncubation in basal medium (Cambrex Corp., East Ruth-
rford, New Jersey) supplemented with 0.5% fetal bovine
erum. Cells were then labeled with 10 mol/l Calcein
M (Molecular Probes, Inc., Eugene, Oregon) for 1 h,
rypsinized, washed, counted, and placed in basal me-
ium supplemented with 0.5% fetal bovine serum, insu-
in, transferring, and selenium (Invitrogen, Carlsbad,
alifornia) in 24-well FluoroBlok membrane inserts with
n 8-m pore size (BD Biosciences, Bedford, Massachu-
etts). The TKI SU11218 was added to both the upper
nd lower chambers in duplicate wells at the indicated
oncentrations for 10 min, followed by PDGF-BB (CA-
MC) or VEGF (CA-EC) addition to the lower cham-
ers. Four hours later the fluorescence microscope images
f the lower surface of the inserts were recorded, and the
umber of migrated cells was quantified with ImagePro
oftware (MediaCybernetics, San Diego, California).
wo low-power fields were captured and quantified for
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Adventitial Microvessels After Stenting March 7, 2006:1067–75ach well. The results were expressed as number of
igrated cells as a percent of total cells.
DGFR- phosphorylation. The CA-SMC were starved
or 48 h in basal medium containing 0.2% fetal bovine
erum before stimulation with 50 ng/ml of PDGF-BB for 5
in. The cells were lysed with HNTG/VO4 and receptors
mmunoprecipitated with anti-PDGFR- polyclonal anti-
odies (No. 06-498, Upstate Biotechnology, Lake Placid,
ew York). After fractionation by SDS-PAGE, blots
ere probed for tyrosine phosphorylation with PY99-
iotin (Santa Cruz Biotechnology, Santa Cruz, Califor-
ia) and for protein loading with anti-PDGFR- (Santa
ruz Biotechnology).
tatistical analysis. All measurements were expressed as
ean  SD. Analysis of variance was performed to
ompare Ad-MV number and intimal CSA by 3D micro
T, in SU11218-treated versus untreated, stented arter-
es at each time point. A Bonferroni correction was
pplied to adjust for multiple comparisons. Student’s t
est was used to compare Ad-MV CSA by 3D micro CT,
njury scores and intima thickness by morphometry, and
ntimal CSA by IVUS between SU11218 and the
lacebo-treated animals at the four-week time point. For
he migration assays, Dunnett’s t test was used to
ompare the mean of each SU11218-treated group with
he mean positive control (PDGF-stimulated CA-SMC
nd VEGF-stimulated CA-EC). Pearson’s correlation
oefficient was performed to assess the relationship be-
ween the number of Ad-MV and in-stent intimal CSA.
tatistical significance was defined as p  0.05.
ESULTS
ffects of stenting on Ad-MV. Arterial stenting resulted
n a significant increase in the number of Ad-MV/segment
t 1 week (24  7 vs. 16  2 in uninjured, p  0.02) that
ersisted up to 4 weeks (23  7 vs. 16  2 in uninjured,
 0.02) (Fig. 3A).
elationship between Ad-MV and IH. At 4 weeks after
tenting, the number of Ad-MV was highly correlated (r 
.77, p  0.001) with in-stent intimal CSA (Fig. 3B).
lthough Ad-MV and IH both increased after stenting, the
atio of Ad-MV to intimal CSA was significantly higher at
week compared with 4 weeks after stenting (26.72  3.17
s. 8.37  6.05, respectively, p  0.001) (Fig. 3C).
issue hypoxia after stenting. The HIF-1 alpha expres-
ion was increased in the arterial wall at 1 week and at 4
eeks compared with uninjured arteries (Fig. 4A). Vessel
all hypoxia, based on pimonidazole adducts, was evident
t 48 h, 1 week, and 4 weeks after stenting compared
ith uninjured arteries (Fig. 4B). Immunohistochem-
stry (Fig. 4C) localized the tissue hypoxia to the medial/
dventitial border of the arterial wall. No tissue hypoxia
as present in uninjured arteries treated with pimonida-
ole (Fig. 4B). cffects of SU11218 in vitro. DNA SYNTHESIS. The TKI
U11218 inhibited PDGF-stimulated CA-SMC prolifera-
ion in a dose-dependent manner, with an IC50 value of 25
mol/l (Fig. 5A). The compound also inhibited VEGF-
nduced CA-EC proliferation in a dose-dependent manner,
ith an IC50 value of 67 nmol/l (Fig. 5B).
ELL MIGRATION. The TKI SU11218 resulted in a signif-
cant inhibition of both PDGF-induced CA-SMC migra-
ion and VEGF-induced CA-EC migration at 0.1 mol/l
igure 3. Temporal profile of Ad-MV after stenting. (A) A marked increase
n the number of microvessels was present at both 1 week and 4 weeks. (B)
orrelation between Ad-MV and in-stent intimal hyperplasia (IH) at 4 weeks.
C) Number of Ad-MV to intimal cross-sectional area (CSA) ratio was
ignificantly higher at 1 week compared with 4 weeks after stenting.oncentration (Figs. 5C and 5D).
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March 7, 2006:1067–75 Adventitial Microvessels After StentingDGFR- PHOSPHORYLATION. The TKI SU11218 resulted
n nearly complete inhibition of PDGF-induced phosphor-
lation of PDGFR- at 0.1 mol/l (Fig. 6). These differ-
igure 4. Tissue hypoxia in the arterial wall. (A) Hypoxia-inducible
actor (HIF)-1 alpha expression was increased at all time points after
tenting (upper panel). (B) Pimonidazole adducts were identified at all
ime points after stenting (upper panel). Protein loading was assessed
y Ponceau-red staining (lower panel of A and B). (C) Immunohis-
ochemistry showing pimonidazole adducts (stained brown) at the
edia/adventitia border at 1 week after stenting. Isch-m  ischemic
uscle  pimonidazole; UI  uninjured artery; UI-P  uninjured 
imonidazole.nces in receptor phosphorylation were not due to an altered pumbers of receptors, as demonstrated by a parallel blot of
DGFR- protein.
ffects of SU11218 in vivo. AD-MV. The TKI SU11218
ignificantly inhibited the formation of Ad-MV at 1 week
9  2 Ad-MV/segment vs. 24  7 in placebo-treated
nimals, p  0.001) and 4 weeks (16  5 Ad-MV/segment
s. 23  7 in placebo-treated animals, p  0.001) after
tenting (Figs. 7A and 8). In addition, the mean Ad-MV
SA was significantly reduced in SU11218-treated animals
0.15  0.05 mm2 vs. 0.25  0.04 mm2 in the placebo-
reated animals, p  0.008) at 4 weeks.
H. The IH was significantly reduced at 4 weeks in the
U11218-treated group compared with placebo by all pa-
ameters (IVUS, 3D micro CT, and morphometry). Intra-
ascular ultrasound assessment showed that intimal CSA
as reduced by approximately 80% in the SU11218-treated
roup (0.52 0.51 vs. 2.47 1.66 mm2 in placebo-treated,
 0.001) (Fig. 7B). The intimal CSA by IVUS and 3D
icro CT showed excellent correlation (r  0.96, p 
.001). Morphometric analysis also showed approximately
0% reduction in intimal thickness in SU11218-treated
nimals (0.13  0.07 mm vs. 0.24  0.13 mm in placebo,
 0.03). There were no differences in injury scores
etween the two groups.
ISCUSSION
ur results indicate that coronary arterial stenting causes
issue hypoxia in the vessel wall that persists for at least 4
eeks. There is concurrent increased expression of the
ypoxia responsive transcription factor, HIF-1 alpha, a
otent regulator of the pro-angiogenic growth factors. After
n initial decrease in the number of Ad-MVs immediately
fter stenting, there is a marked increase in Ad-MV. This
d-MV response precedes the development of IH, and the
agnitude of this response significantly correlates with the
mount of IH. Furthermore, SU11218, a TKI, significantly
nhibits both Ad-MV formation and IH.
An increase in Ad-MV has been shown in several
iseases affecting the arterial wall (16–19), but limited
nformation is available regarding their relationship to
rterial repair after vascular injury. In balloon-injured cor-
nary arteries, Ad-MV density was increased by 4 weeks
fter vessel injury and the number of Ad-MV correlated
ith percent lumen stenosis (4). Pels et al. (5) showed that
d-MV, evaluated by histology only, occurred within three
ays after balloon injury. Regression of Ad-MV in this
alloon-injury model at the time of arterial narrowing
uggested that changes in the adventitial microvasculature
ight be an important component of arterial remodeling
fter balloon angioplasty. To date, no study has assessed
hanges in Ad-MV after coronary stenting.
This study is the first to perform 3D micro CT to
uantify Ad-MVs in intact specimens containing metal
tents. Although this technique has been previously re-
orted in animal vascular injury models (4,19), its use in
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Adventitial Microvessels After Stenting March 7, 2006:1067–75oronary stents has been limited by image artifacts associ-
ted with the dense metal structure. These artifacts were
educed in this study through the use of a high-quality scan
rotocol, which included the use of added filtration (copper
nd aluminum) to reduce beam-hardening artifacts and
mprove image quality directly adjacent to the stent. The
umber of Ad-MV in uninjured porcine coronary arteries
igure 5. In vitro effects of SU11218. A tyrosine kinase inhibitor, SU112
mooth muscle cell (CA-SMC) proliferation (A), vascular endothelial
roliferation (B), PDGF-stimulated CA-SMC migration (C), and VEG
romo-dexoyuridine.
igure 6. Effects of SU11218 on platelet-derived growth factor receptor-
eta (PDGFR-) phosphorylation. The SU11218 inhibited phosphoryla-
ion of the PDGFR- in a dose dependent manner. The lower panelg
hows equal protein loading of PDFGR-. IP immunoprecipitation; pY
phosphorylated PDGFR-beta; WB  Western blot.etermined by 3D micro CT was similar to a previous
eport that used histology (5). In injured vessels, 3D micro
T can accurately identify functioning Ad-MV (with a
esolution of 16 m). In contrast, histology only shows
ndothelial-lined channels, which might not be functional.
Our study demonstrates vessel wall hypoxia is present
arly after vascular stenting and might be an important
timulus for the angiogenic response. The initial hypoxic
esponse in the medial-adventitial layers after stenting is
ikely related to the deep vascular injury to the vasa vasorum
s a direct consequence of stent deployment, because there
as a significant decrease in the number of Ad-MVs at 48 h
fter stenting. Tissue hypoxia is a potent stimulus for
ngiogenesis (20,21) and the release of growth factors, such
s VEGF (22), PDGF (6,23), endothelin (24), IL-6 (25),
nd plasminogen activator inhibitor-1 (26), that play a
ritical role in both neovascularization and the development
f intimal hyperplasia. Despite the significant increase in
d-MV at 1 week and 4 weeks after stenting, arterial wall
ypoxia persisted throughout the study period. The pro-
ibited platelet-derived growth factor (PDGF)-stimulated coronary artery
h factor (VEGF)-stimulated coronary artery endothelial cell (CA-EC)
mulated CA-EC migration (D) in a dose-dependent manner. BrdU 18 inh
growtressive thickening of the vessel wall is an important
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March 7, 2006:1067–75 Adventitial Microvessels After Stentingeterminant of oxygen demand (27) and is likely an impor-
ant contributor to this ongoing hypoxic response in the
essel wall.
igure 7. In vivo effects of SU11218. (A) The SU11218 significantly
nhibited the Ad-MV response after stenting at 1 week and 4 weeks.
B) The SU11218 resulted in approximately 80% reduction in the amount
f IH at 4 weeks. Abbreviations as in Figures 2 and 3.
igure 8. Representative cross-sectional (A to C) and maximum intensity p
A, D), stented and placebo-treated (B, E, respectively), and stented and
rojection of image intensity along the axial direction, obtained over a 2-m
icrovessels (Ad-MV) (arrowhead) appear as white dots behind the stemages. There was a significant increase in Ad-MV at 4 weeks after stenting
) or SU11218-treated animals (C, F). White bar  2 mm.Adventitial microvessel formation is mediated through
omplex interactions between several growth factors and
ytokines. Both VEGF and PDGF are important angio-
enic growth factors that mediate cell signaling through
eceptor tyrosine kinase and are up-regulated during tissue
ypoxia (6,22). Whereas VEGF initiates angiogenesis by
timulating EC, PDGF plays a central role in recruitment of
ericytes and SMC to form more stable microvessels (8,9).
nti-angiogenic therapies have traditionally targeted
EGF signaling alone, but recent data suggest that block-
ng PDGFR- might provide incremental effects (11). We
sed SU11218 to inhibit angiogenesis in our model, because
t targets receptor tyrosine kinases and inhibits both
EGFR and PDGFR- activation. The TKI SU11218
nhibited in vitro EC and SMC migration and proliferation
n a dose-dependent manner. Moreover, SU11218 signifi-
antly inhibited both the in vivo adventitial angiogenic
esponse and the formation of IH; however, our study
esults can not determine the extent to which the effects on
H are related to the inhibition of the Ad-MV or the
nhibition of PDGFR- signaling on intimal SMC.
Angiogenic inhibitors have been successfully used to inhibit
he angiogenic response in atherosclerotic lesions and prevent
rogression of atherosclerosis in apolipoprotein-E–deficient
ice (28,29). Inhibition of plaque neovascularization reduced
acrophage accumulation and progression of advanced ath-
rosclerosis (29). With regard to vascular injury, there have
een conflicting reports on the predominant effect of angio-
enic growth factors and inhibitors on arterial repair process
30–37). Although Ad-MV has been previously correlated
ith neointima formation after non-stent experimental arterial
njury (4,34,36), the effects of VEGF expression or blockade on
he development of intimal hyperplasia have been variable
ion (MIP) (D to F) images obtained from 3D micro CT scans of uninjured
1218-treated arteries (C, F, respectively). The MIP images represent a
hick sample region. Arrow  stent. I  intima; L  lumen. Adventitial
uts in cross-sections and as bright annulus external to the stent in MIProject
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alloon injury have been attributed to accelerated re-
ndothelialization (30,35), whereas the untoward effects, stim-
lation of intimal hyperplasia, might be mediated by recruit-
ent of inflammatory cells (34,37) and promotion of Ad-MV
ormation (36). The results of VEGF treatment on the
evelopment of IH have also been inconclusive in experimental
tent injury models. A reduction in the development of IH by
EGF therapy has been reported in some studies (31,33),
hereas others have demonstrated a lack of benefit with this
pproach (32,38).
The conflicting results in both balloon injury and stenting
odels show the complex relationship between VEGF and
he arterial repair process and are likely related to method-
logical differences among these studies. The effects of
ngiogenic growth factor or inhibitor administration after
rterial injury might be related to the type of injury (balloon
s. stent), extent of injury (superficial vs. deep), site of
elivery (intraluminal vs. adventitial), as well as timing and
uration of angiogenic growth factor or inhibitor adminis-
ration. Endothelial denudation with minimal arterial wall
amage and/or a brief local/intraluminal VEGF exposure
ight have a predominant effect of enhanced re-
ndothelialization of the injured segments, whereas injury to
eeper vascular layers and prolonged VEGF exposure,
ystemic or peri-adventitial, might have an opposite effect
n intimal growth by enhancing Ad-MV formation. This
atter concept is supported by the inhibition of intimal
yperplasia after balloon injury with inhibitors of angiogen-
sis (34,36) and now reported in the present study with stent
njury. Further studies are required to understand the
nteractions between various factors contributing to these
ariable responses.
onclusions. Arterial stenting is associated with tissue hyp-
xia in the vessel wall and generates a significant Ad-MV
esponse. A TKI, SU11218, inhibits both the increase in
d-MV and IH. Compounds like SU11218 might therefore
ave an important therapeutic role in the prevention of
estenosis after arterial stenting.
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